BTK Locus Gene Editing in HSCs for Physiologic XLA Correction

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current treatments for X-linked agammaglobulinemia (XLA), such as intravenous immunoglobulin supplementation and viral vector-mediated gene addition, are imperfect due to high costs, lifelong requirements, risks of graft rejection, and potential oncogenesis, necessitating a safer and more permanent cure.

Innovation Solution

The use of the CRISPR/Cas9 platform for targeted gene correction and in-frame insertion of a corrective BTK gene into the BTK locus in human CD34+ hematopoietic stem cells, integrated with an endogenous promoter to ensure physiological regulation.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If viral vector-mediated gene addition is used to treat XLA, then BTK function is restored, but insertional oncogenesis risk and abnormal myeloproliferation occur

Engineering Contradiction:

ImproveBTK function restorationVSAvoidinsertional oncogenesis risk

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent extracts the harmful viral vector delivery system and replaces it with a non-viral, targeted gene correction approach using CRISPR/Cas9. This removes the source of insertional oncogenesis while preserving the therapeutic benefit of BTK restoration through precise editing of the endogenous BTK locus

Inventive Principle:

Principle #2Taking out (Extraction)

Solution Approach 2:

The patent replaces the mechanical/viral insertion mechanism with a precision molecular editing mechanism. Instead of relying on viral vectors to randomly integrate genetic material, the invention uses CRISPR/Cas9 guided by gRNA to precisely edit the BTK gene at its native locus, eliminating uncontrolled insertion events that cause oncogenesis

Inventive Principle:

Principle #28Mechanics substitution (Replace mechanical system)

2Reliability

If overexpression of BTK is achieved through viral vector delivery, then BTK function is enhanced, but abnormal myeloproliferation occurs

Engineering Contradiction:

ImproveBTK functionVSAvoidabnormal myeloproliferation

Core Design Contradiction:

ReliabilityVSObject-generated harmful factors

Solution Approach 1:

The patent applies local quality control by restoring BTK function specifically at the endogenous BTK locus rather than through global overexpression. The CRISPR-mediated editing precisely corrects or replaces the mutated BTK sequence in situ, ensuring that BTK expression levels remain physiologically appropriate while still restoring function

Inventive Principle:

Principle #3Local quality

Solution Approach 2:

Instead of adding extra copies of BTK through viral vectors (overexpression approach), the invention inverts the strategy by directly correcting the endogenous BTK gene. This approaches the problem from the opposite direction—fixing the existing gene rather than adding new copies—thereby avoiding overexpression-related myeloproliferation

Inventive Principle:

Principle #13The other way round (Inversion)

3Reliability

If immunoglobulin supplementation is used to treat XLA, then antibody deficiency is compensated, but lifelong treatment and high costs are required

Engineering Contradiction:

Improveantibody response compensationVSAvoidtreatment duration

Core Design Contradiction:

ReliabilityVSDuration of action of moving object

Solution Approach 1:

The patent applies preliminary action by permanently correcting the genetic defect in hematopoietic stem cells before the patient would require lifelong immunoglobulin supplementation. The CRISPR-mediated gene correction in HSCs creates a lasting fix that restores endogenous BTK function, eliminating the need for continuous external antibody replacement therapy

Inventive Principle:

Principle #10Preliminary action

Solution Approach 2:

The invention creates a permanent genetic copy of the functional BTK gene within the patient's own hematopoietic stem cells. Instead of repeatedly administering external immunoglobulins, the corrected BTK gene serves as a self-sustaining template that continuously produces functional BTK protein, replacing the need for lifelong supplementation

Inventive Principle:

Principle #26Copying

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

This approach provides a potentially curative therapeutic option by achieving low-frequency but effective correction of BTK expression, reducing immunodeficiencies in XLA patients with minimal risk of insertional oncogenesis.

Implementation Method 1

The discovery of meganucleases in the mid-1990's (e.g., Sce-I) marked the beginning of using endonucleases that could create double-strand breaks and promote homologous recombination by almost five orders of magnitude

Methodology Applied

Scientific EffectHomologous recombination:

Data Source

PatentUS12492411B2Gene editing of monogenic disorders in human hematopoietic stem cells—correction of X-linked agammaglobulinemia (XLA)

Publication Date: 2025.12.09 RGT UNIV OF CALIFORNIA

AI summary

In certain embodiments methods of treating X-Linked agammaglobulinemia (XLA) in a mammal are provided where the methods comprise: i) providing differentiated T cells and/or stem/progenitor cells from the mammal; ii) performing a targeted insertion of a corrective BTK cDNA at the BTK gene locus in said cells to provide a corrected BTK gene in said cells; and iii) introducing said cells into said mammal where said corrected BTK gene is expressed in a physiologically regulated manner.